Abeona Therapeutics Announces FDA Allowance of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Abeona Therapeutics Announces FDA Allowance of Investigational New Drug (IND) for Systemic AAV Phase 1/2 Clinical Study With ABO-102 Gene Therapy for Patients With Sanfilippo Syndrome Type A (MPS IIIA)

NEW YORK, NY and CLEVELAND, OH --(Marketwired - February 29, 2016) -

  • Phase 1/2 dose escalation study of ABO-102 in 6-9 patients
  • Natural history study in 25 patients establishes baseline for efficacy endpoints
  • FDA previously granted both Orphan Drug Designation and Rare Pediatric Disease Designation

Abeona Therapeutics, Inc. ( NASDAQ : ABEO ), a biopharmaceutical company focused on developing and delivering products for severe and life-threatening rare diseases, today announced the FDA cleared the Company's Investigational New Drug Application for ABO-102 (AAV- SGSH), a single treatment strategy for Mucopolysaccharidosis Type IIIA (MPS IIIA). The ABO-102 IND application is now active and enables Nationwide Children's Hospital (Columbus, OH) to initiate a Phase 1/2 clinical study designed to assess the safety, tolerability and potential efficacy of ABO-102 in children with MPS IIII A.

"MPS IIIA is a devastating lysosomal storage disease that is caused by a single gene defect. The AAV SGSH gene therapy approach developed by Drs. Douglas McCarty and Haiyan Fu at Nationwide Children's, represents a new treatment paradigm for addressing this relentlessly progressing disease with a single, intravenous administration," noted Kevin M. Flanigan, MD, principal investigator with the Center for Gene Therapy at Nationwide Children's and Professor of Pediatrics and Neurology at The Ohio State University College of Medicine. "We would like to thank these dedicated researchers, as well as the many patient foundations, for their dedicated support and commitment to advancing new treatment options forward for this devastating unmet medical need."

"ABO-102 is well positioned to advance gene therapy trials for patients with Sanfilippo syndrome type A, who have profound neurological deficits, as well as numerous peripheral organ manifestations. In pre-clinical studies, a single intravenous injection of ABO-102 restored the SGSH enzyme activity, and corrected the lysosomal storage pathology throughout the CNS and body," noted Timothy Miller, PhD, President & CEO. "The treatment also led to the correction of astrocytosis and neurodegeneration, hallmarks of secondary neuropathology of MPS IIIA. Importantly, intravenous gene delivery of ABO-102 improved cognitive and motor functions, as well as extended survival in preclinical animal models."

Sanfilippo syndromes (or mucopolysaccharidosis (MPS) type III) are a group of four inherited genetic diseases each caused by a single gene defect, described as type A, B, C or D, which cause enzyme deficiencies that result in the abnormal accumulation of glycosaminoglycans (sugars) in body tissues. MPS III is a lysosomal storage disease, a group of rare inborn errors of metabolism resulting from deficiency in normal lysosomal function. The incidence of MPS III (all four types combined) is estimated to be 1 in 70,000 births. Mucopolysaccharides are long chains of sugar molecules used in the building of connective tissues in the body. There is a continuous process in the body of replacing used materials and breaking them down for disposal. Children with MPS III are missing an enzyme, which is essential in breaking down the used mucopolysaccharides called heparan sulfate. The partially broken down mucopolysaccharides remain stored in cells in the body causing progressive damage. Babies may show little sign of the disease, but as more and more cells become damaged, symptoms start to appear. In MPS III, the predominant symptoms occur due to accumulation within the central nervous system (CNS), including the brain and spinal cord, resulting in cognitive decline, motor dysfunction, and eventual death. Importantly, there is no cure for MPS III and treatments are largely supportive care.

"The progress of ABO-102 into human clinical trials represents a significant milestone in advancing our rare disease product pipeline towards achieving value for patients and their families, as well as shareholders," stated Steven Rouhandeh, Executive Chairman.

About ABO-102 (AAV SGSH): ABO-102 is a next generation adeno-associated viral (AAV)-based gene therapy for MPS IIIA (Sanfilippo syndrome), which involves a one-time delivery of a normal copy of the defective gene to cells of the central nervous system (CNS) with the aim of reversing the effects of the genetic errors that cause the disease. After a single dose in Sanfilippo preclinical models, ABO-102 induced cells in the CNS and peripheral organs to produce the missing enzymes and help repair damage caused to the cells. Preclinical in-vivo efficacy studies in Sanfilippo syndrome have demonstrated functional benefits that remain for months after treatment. A single dose of ABO-102 significantly restored normal cell and organ function, corrected cognitive defects that remained months after drug administration, increased neuromuscular control and increased the lifespan of animals with MPS IIIA over 100% one year after treatment compared to untreated control animals. These results are consistent with studies from several laboratories suggesting AAV treatment could potentially benefit patients with for Sanfilippo syndrome Type A and B, respectively. In addition, safety studies conducted in animal models of Sanfilippo syndromes have demonstrated that delivery of AB0-102 are well tolerated with minimal side effects.

About Abeona: Abeona Therapeutics, Inc. develops and delivers gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona's lead programs are ABO-101 (AAV NAGLU) and ABO-102 (AAV SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). We are also developing ABO-201 (AAV CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, we are also developing rare plasma protein therapies including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD using our proprietary SDF™ (Salt Diafiltration) ethanol-free process. For more information, visit  www.abeonatherapeutics.com .

About Nationwide Children's Hospital: Ranked 7th of only 10 children's hospitals on U.S. News & World Report's 2014-15 "America's Best Children's Hospitals Honor Roll" and among the Top 10 on Parents magazine's 2013 "Best Children's Hospitals" list, Nationwide Children's is one of the nation's largest not-for-profit freestanding pediatric healthcare networks providing care for infants, children and adolescents as well as adult patients with congenital disease. As home to the Department of Pediatrics of The Ohio State University College of Medicine, Nationwide Children's faculty train the next generation of pediatricians, scientists and pediatric specialists. The Research Institute at Nationwide Children's is one of the Top 10 National Institutes of Health-funded free-standing pediatric research facilities in the U.S., supporting basic, clinical, translational and health services research at Nationwide Children's. The Research Institute encompasses three research facilities totaling 525,000 square feet dedicated to research. More information is available at NationwideChildrens.org/Research.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include, without limitation, our plans for continued development and internationalization of our clinical programs, management plans for the Company, and general business outlook. These statements are subject to numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to develop our products and technologies; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.

Company and Media Contacts: Andre'a Lucca Vice President of Communications & Operations Abeona Therapeutics, Inc. +1 (212)-786-6208 alucca@abeonatherapeutics.com Magdalena Tyrpien Director of Investor Relations Abeona Therapeutics, Inc. +1 (212)-786-6209 mtyrpien@abeonatherapeutics.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Misunderstood Brands Bets Small Cans Can Scale Growth

Updated Category News Views 177

A tiny cocktail can is a brutal little test of whether a spirits brand has legs. Misunderstood Brands is putting four 100mL offerings on the shelf just as its Wegmans distribution expands across the East Coast, and that combination matters more than another glossy flavor announcement. The company is trying to turn products people discovered in bars and restaurants into...

Continue Reading
Innoviz's 1-for-20 Split Is a Listing Lifeline Test

Updated Category News Views 79

A twenty-share pile of INVZ is about to become one share, and nobody should confuse that paperwork with a turnaround. Innoviz plans to enact a 1-for-20 reverse split at 11:59 p.m. Eastern on Friday, December 4, with split-adjusted trading expected when Nasdaq opens on December 7. This is a blunt instrument aimed at one immediate problem: getting the quoted share price...

Continue Reading
DigiKey’s Arduino Webinar Puts Edge AI Hardware to Work

Updated Category News Views 68

A Small Board With a Big Practical Question Edge AI is finally getting dragged out of the slide deck and onto the workbench, which is where it ought to prove itself. DigiKey plans to host a free 60-minute webinar on Dec. 2, 2026, at 10 a.m. CST covering Arduino’s new VENTUNO Q edge AI computer. The session promises a hardware tour, an Arduino App Lab walkthrough, and a...

Continue Reading
OCEG Faces China's Demographic Test After 40 Years

Updated Category News Views 61

A school group that once opened 35 kindergartens in a year is admitting the old playbook has run its course. That is the real message behind Oriental Cambridge Education Group's 40th-anniversary talk, not the balloons and ceremonial language. OCEG operates more than 170 institutions across 39 Chinese cities, and its chairman, Yu Yue, says the next chapter will be judged...

Continue Reading
Ampace Fire Test Gives Data Centers Useful Evidence

Updated Category News Views 150

Battery cabinets are becoming the awkward guest in the AI data-center boom: absolutely necessary, expensive to install, and nobody wants to discover their failure behavior during a real emergency. Ampace’s newly presented PU100 large-scale fire-test results deserve attention for that reason. This is not a magic safety stamp, and the company says the findings apply only...

Continue Reading
Century's Florence Model Openings Put Arizona in Focus

Updated Category News Views 72

Six furnished houses in Florence may sound like a modest ribbon-cutting, but homebuilding is a business of small field signals before the quarterly numbers ever show up. Century Communities is scheduled to host a November grand opening for six model homes spanning two new communities in Florence, Arizona. For investors tracking NYSE:CCS, that is not a thesis by itself. It...

Continue Reading
Roland DG's Brand Refresh Earns Three B2B Awards in 2026

Updated Category News Views 57

Three trophies for a printer-maker’s marketing overhaul will not move mountains by themselves, but they do tell us Roland DG has stopped treating its brand like an afterthought. The company’s global Make Your Mark refresh picked up two Silver awards and one Bronze at the 2026 Drum B2B Awards in Miami. For a business selling industrial-grade tools into crowded,...

Continue Reading
AWK Adds Fayette Water System With $9M Upgrade Plan

Updated Category News Views 121

Small water systems do not usually collapse in one dramatic heap; they get worn down by scattered pipes, compliance demands, thin staffing and bills nobody wants to raise. That is the backdrop for Pennsylvania American Water’s completed $32.8 million purchase of the Indian Creek Valley Water Authority system. For American Water shareholders, this is the familiar...

Continue Reading
A Hybrid Book Bets on Muscles, Myth, and Machines

Updated Category News Views 32

Few publishing pitches ask readers to carry a barbell into Tartarus, but A R Quigley is plainly not chasing the middle of the bookstore. Doctrina Machina Learning Machine, released by Palmetto Publishing in November 2026, welds together a strength-training guide and an underground military science-fiction war story. That is an odd little contraption, no use pretending...

Continue Reading
Visual Cipher Bench Exposes AI Agents' Hidden Rule Gap

Updated Category News Views 130

Forty little black-and-white puzzles just threw a bucket of cold water on the autonomous-agent sales pitch. Einsia AI’s Navers Lab says its new Visual Cipher Bench found that the best result among eight frontier models was only 26.7%, with no tested configuration clearing 30%. That is not a minor blemish. It is a reminder that a model can sound clever, use tools, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Private Aviation's Trust Crisis Amid Industry Consolidation

Updated Category News Views 182

The landscape of private aviation is transforming under a weighty cloak of financial strain and operational challenges. With recent disruptions in commercial flights grabbing headlines, travelers are sharpening their focus on safety rather than brand allure. As operators in this space grapple with tightening regulations and fluctuating customer expectations, the spotlight...

Continue Reading
CPSC Warns Against Hazards of EnHomee Tall Dressers

Updated Category News Views 329

Warning Issued on EnHomee Tall Dressers The U.S. Consumer Product Safety Commission (CPSC) has issued an urgent warning, advising consumers to stop using the EnHomee tall fabric dressers immediately. These dressers pose significant risks due to their instability if not securely anchored to the wall, potentially leading to serious injuries or even fatalities from tip-over...

Continue Reading
UK Retailers Adopt Automation Amid Rising Costs Challenges

Updated Category News Views 288

UK Retailers Turn to Automation for Savings Big retailers in the UK are ramping up their push for efficiency as they navigate rising operational costs. Key players such as Tesco (OTC: TSCDY), Sainsbury (LON: SBRY), Marks & Spencer, and Next (LON: NXT) are exploring automation and other cost-saving measures to maintain competitive pricing for their customers. Challenges...

Continue Reading
CenterPoint Energy Announces Increased Quarterly Dividend Payout

Updated Category News Views 154

CenterPoint Energy Announces New Dividend Rate CenterPoint Energy, Inc. has declared a regular quarterly cash dividend of $0.2200 per share for its common stock. This announcement was made by the Board of Directors and continues to showcase the company's commitment to shareholders. The dividend will be payable to stockholders of record on a specified date. This adjustment...

Continue Reading
Cincinnati Financial Reports Impressive Q3 Growth Figures

Updated Category News Views 73

Cincinnati Financial's Q3 Performance Overview Cincinnati Financial Corporation (NASDAQ: CINF) has recently unveiled its third-quarter results for the year, revealing a compelling narrative of growth despite some challenges in earnings. The insurer managed to outperform revenue expectations, posting impressive results that caught the eye of analysts and investors alike....

Continue Reading